Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Plague, Anthrax, and ASM, Oh My! With ASM president Virginia Miller and president-elect Theresa Koehler

Plague, Anthrax, and ASM, Oh My! With ASM president Virginia Miller and president-elect Theresa Koehler

FrommicroTalk


Plague, Anthrax, and ASM, Oh My! With ASM president Virginia Miller and president-elect Theresa Koehler

FrommicroTalk

ratings:
Length:
45 minutes
Released:
Oct 18, 2023
Format:
Podcast episode

Description

Plague and anthrax are feared diseases due to high mortality rates following pulmonary exposure, and both are considered potential bioweapons.  Dr. Virginia Miller, professor at the University of North Carolina at Chapel Hill and ASM President, studies plague, as well as other Gram negative bacteria. Dr. Theresa Koehler, emeritus professor at UTHealth Houston and ASM president-elect, is an expert in anthrax.  microTalk caught up with Dr. Miller and Dr. Koehler at ASM Microbe 2023 in Houston to discuss these biothreat agents. Dr. Miller discusses why she studies plague, the differences between bubonic and pneumonic plague, why Klebsiella pneumoniae poses a growing health threat, and what it was like being John Mekalanos’ first Ph.D. student. Dr. Koehler discusses why anthrax is considered a potential bioweapon, why significant scientific progress was made following the anthrax attacks of 2001, why gardeners shouldn’t worry about catching anthrax, and her first failed experiment.  Both discuss their vision for ASM and the role it plays in microbiological research and society. Participants: Karl Klose, Ph.D. (UTSA) Virginia Miller, Ph.D. (UNC Chapel Hill) Theresa Koehler, Ph.D. (UT Health Houston) Janakiram Seshu, Ph.D. (UTSA) Jesus Romo, Ph.D. (UTSA)
Released:
Oct 18, 2023
Format:
Podcast episode

Titles in the series (81)

The talks from the researchers in the field of infectious diseases. The podcast is hosted by South Texas Center for Emerging Infectious Diseases (STCEID).